Top Articles
#1 in Business Subscribe Email Print

You are here: Home > Finance > Investing > Tattle Tail

Tags

  • product
  • there
  • about
  • developing combination
  • developing combination

  • Links

  • Paid Survey Scams - The Shocking Report
  • Business Process Outsourcing for Small Business
  • Bad Credit Loans Help You in Rainy Days
  • Top Articles - Tattle Tail

    When I was in grade three I had this odious teacher that hated kids who squealed on other kids, regardless of the issue. It didn’t matter if you complained about someone steal
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    ing an eraser, cheating on a test, taking your lunch money, or socking you in the mouth...she didn’t want to have to deal with it. To her, integrity was found in silence.

    If
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    ou were affronted by a fellow student and happened to mention it to her, she would respond by a) disregarding you, and b) pinning a long donkey’s tail fashioned out of constru
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    tion on your behind with the words “tattle tail” emblazoned on it.(you had to wear it for the remainder of the day). I tried to make it look fashionable

    Personally, I’d like
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    to think that the lessons we learned in elementary school help us out later on in life. If so, I’m certainly glad that Sherron S. Watkins wasn’t in my class. As you may, or ma
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    not know, Sherron S. Watkins was the Vice President of Corporate Development at Enron who told then CEO Ken Lay in a now-famous August 2001 memo that financial fraud could de
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    troy the energy trading firm. She said his response was to launch a "bogus" probe and try to have her fired.

    It was less than four months before Enron collapsed into bankrupt
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    cy at a cost of thousands of jobs and billions of dollars of stock-market wealth.

    Enron's downfall sparked a federal investigation that resulted in the multiple fraud and con
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    piracy charges for which Lay, 63, and Skilling, 52, are now on trial. The two face decades in prison if convicted.

    Did anything positive come out of the Enron debacle? I thin
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    we can finger two silvery-gray lined clouds. First, it’s all about integrity. Ordinary people matter. Determination matters. Honesty matters. Diligence matters. There is a pl
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    ce for Truth.

    Secondly...the Sarbanes-Oxley Act. The Sarbane Oxley Act of 2002 is considered to be one of the most significant changes to federal securities law. It came in t
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    he wake of a series of corporate financial scandals, including those affecting Enron, Arthur Andersen, and WorldCom.

    Among the major provisions of the act are: criminal and c
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    vil penalties for securities violations, auditor independence / certification of internal audit work by external auditors and increased disclosure regarding executive compensa
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    ion, insider trading and financial statements.

    In the world of publicly traded companies, there is a lot at stake. Not only are the companies responsible for their staff, cli
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    ents, partners, and customers, they’re also responsible to the every-day, well intentioned, share holder who has chosen, rightly or wrongly, to believe that what the company s
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    ys is true...is actually True.

    We need to be able to trust the people in charge. Whenever a company does something noteworthy, the CEO is often the first one to step into the
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    limelight and take the credit along with a big fat bonus. (Lay raked in $150 million in income, bonuses and stock packages. He still sleeps soundly every night in one of his s
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    everal mansions.) But, when things are bleak, some CEO’s seem to disappear into a world of meetings.

    Integrity, honor and truthfulness aren’t just virtues meant for the third
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    grade. They’re qualities for life...and what a better place the stock market (and society at large) would be if everyone lived these virtues more often.

    While the stock marke
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    is still full of inherent risks...it may be just a little safer than it use to be. So hats off to Whistle Blowers like Sherron S. Watkins...and leave the donkey tails at home


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.toparticles.org.ua/article/103722/toparticles-Tattle-Tail.html">Tattle Tail</a>

    BB link (for phorums):
    [url=http://www.toparticles.org.ua/article/103722/toparticles-Tattle-Tail.html]Tattle Tail[/url]

    Related Articles:

    The Shocking Truth About Paid Surveys

    Virtual Assistants, Actual Savings

    The Future of eBook Book Markers and Adsense Cometh

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com